Analysts' ratings for Alnylam Pharmaceuticals ALNY over the last quarter vary from bullish to bearish, as provided by 27 ...
MedPage Today on MSN4d
STRIDE: Semaglutide Shows It Has Legs in Peripheral Artery DiseaseCHICAGO -- Semaglutide further solidified its efficacy for diabetes-associated cardiovascular conditions, this time building ...
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price upped by research analysts at Scotiabank from ...
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its target price increased by Stifel Nicolaus from $300.00 to ...
Fintel on MSN2d
Redburn Atlantic Initiates Coverage of Alnylam Pharmaceuticals (ALNY) with Buy RecommendationFintel reports that on March 31, 2025, Redburn Atlantic initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a ...
The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...
In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price ...
Zacks.com on MSN1d
SNY Gets FDA Nod for First Ever Hemophilia Drug in the United StatesThe FDA approves Sanofi's Qfitlia as the first therapy in the United States to treat hemophilia A or B with or without ...
Alnylam Pharmaceuticals saw a 13% share price increase in the last quarter, propelled by the FDA approval of Qfitlia™ for hemophilia A or B, a significant milestone reflecting its leadership in ...
In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on Alnylam Pharma (ALNY – Research Report), with a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback